Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Acorda Therapeutics (ACORQ) has shared an announcement.
Acorda Therapeutics, Inc. has finalized an asset sale to Merz Pharmaceuticals for $185 million, after filing for Chapter 11 bankruptcy. The company’s equity will be canceled, with no distributions to equity holders, as a Liquidation Plan takes effect. A Liquidating Trustee will manage the sale proceeds and handle the company’s dissolution, representing a significant shift in the company’s trajectory and a cautionary tale for investors in similar situations.
Learn more about ACORQ stock on TipRanks’ Stock Analysis page.